TAIPEI, Taiwan, Oct. 1, 2015 /PRNewswire-iReach/ -- Senhwa Biosciences, a biotechnology company focused on bringing forward novel targeted therapy for cancer, would like to congratulate Tak W. Mak and Samuel Aparicio for being awarded the prestigious Stand Up To Cancer Canada (SU2C-Canada) Canadian Breast Cancer Foundation (CBCF) Breast Cancer Dream Team research funding. They will direct a Dream Team made up of Canada’s leading cancer experts to develop new therapies that will benefit the breast cancer patients. (SU2C Canada: AACR)
Photo - http://photos.prnewswire.com/prnh/20150930/272581LOGO
SU2C Canada is also partnering with CBCF, with support from CIBC, as well as the Ontario Institute for Cancer Research (OICR) which is funding clinical trials in the province of Ontario, to fund this Breast Cancer Dream Team, for a total of CAD$9 million, over four years. AACR International Canada Research (AACR) is SU2C Canada’s scientific partner.
Stand Up To Cancer Canada (SU2C-Canada), a charitable program of EIF Canada, supports, funds and drives basic lab research into lifesaving treatments. “The goal is to attack cancer by bringing the best and most talented possible people together, fund them generously, oversee their progress rigorously and shoot for big payoffs on a tight schedule.” Saporito, Bill. “The Conspiracy to End Cancer” TIME. April 1st 2013.
Teams selected are reviewed by SU2C Canada Scientific Advisory Committee semiannually, keeping the top scientists on their toes in achieving real results of patients’ survival in cancer treatments, faster. “When you have to answer to Nobel laureates and other, it’s a very tough review team” says Dr. Daniel Von Hoff, chief Scientific Officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and physician in chief at the Translational Genomics Research Institute. (Quoted from “The Conspiracy to End Cancer”, TIME. April 1st, 2013)
The investigational product CX-5461 is supported by Senhwa Biosciences. “We look forward to having the SU2C Canada CBCF Breast Cancer Dream Team make use of our investigational product to research valuable new treatment options for patients with breast cancer” said John Soong, MD, Senior Medical Officer at Senhwa biosciences.
CX-5461 is currently being evaluated in an ongoing Phase I for the treatment of hematologic malignancies.
The preparation of the formal agreement between the SU2C Canada CBCF Breast Cancer Dream Team institutions and Senhwa Biosciences is currently in progress.
MEDIA CONTACTS:
SU2C Canada / Jane Rubinstein / jrubinstein@standup2cancer.ca / 646-386-7969
AACR International Canada / Rick Buck / rick.buck@aacr.org / 215-446-7162
Senhwa Biosciences / Kenner Wang / kenner.wang@senhwabio.com / +886-2-89131956 ext.216
About EIF Canada / Stand Up To Cancer Canada
EIF Canada, a Canadian registered charity (Reg. # 80550 6730 RR0001), founded by the U.S.-based Entertainment Industry Foundation, was established to conduct charitable programs in Canada addressing health and other issues. Stand Up To Cancer Canada (SU2C Canada) is a program of EIF Canada that raises funds to support collaborative research teams, as well as education and awareness programs conducted in Canada. For more information on Stand Up To Cancer Canada, visit http://www.standup2cancer.ca.
AACR International Canada
The mission of AACR International Canada is to prevent and cure cancer through research, education, communication, and collaboration. AACR International Canada convenes topical scientific conferences; offers educational workshops, fellowships, and research grants; collaborates with cancer survivors; raises public awareness of the progress in cancer research; and advocates for strong research funding. As the Scientific Partner to Stand Up to Cancer Canada, AACR International Canada provides scientific oversight and conducts expert peer review and grants administration. For more information, please visit www.AACRCanada.ca.
Senhwa Biosciences
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept. Senhwa is headquartered in Taiwan, but with subsidiary located in San Diego, CA, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia, Canada, the USA and Asia, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabiosciences.com.
Media Contact:Kenner Wang, Senhwa Biosciences, Inc., +886 289131956 ext. 216, kenner.wang@senhwabio.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Senhwa Biosciences
Help employers find you! Check out all the jobs and post your resume.
